LMCE2020

[SY13]
CAP-KSLM Session
Cardiac markers 2021

[SY14]
KDCA-KSLM Session
Strengthening public-private cooperation in laboratory medicine for infectious diseases in the post-COVID era

[PL03]
Point of care molecular testing

[EW13]
Abbott Korea

The value proposition for laboratory medicine has long been theorized, estimated and debated. Despite decades of effort and intangible proof, the strategic value of the profession is often overlooked and under-valued. This workshop explores the integral connections of data insights to measurably better healthcare performance.

[KS04]
How to implement a PBM program at your hospital

[EW14]
LG Chem

Vaccines work primarily by simulating natural infection, promoting the development of humoral and cellular immune responses to defend the host against specific viral pathogen. With respect to the biological aspects, the currently used mRNA-LNPs contain genetic material encoding a recombinant form of SARS-CoV-2 spike protein with its receptor-binding domain (RBD), and are hence effective to stimulate B cells to generate neutralizing antibodies directed against the spike protein, thus reducing binding effectiveness with receptors at the host cell surface, and enhancing virus inactivation and clearance. Currently used vaccines contains genetic material encoding a recombinant form of the SARS-CoV-2 spike protein with a receptor binding domain (RBD), therefore it is effective in stimulating B cells to produce neutralizing antibodies. It reduces the binding effect of spike protein with receptors on the host cell surface (particularly angiotensin converting enzyme 2; ACE2) and improves virus inactivation and clearance.

[EW15]
bioneer

Rapid and accurate detection of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is essential for successfully controlling the current global COVID-19 pandemic.
We will cover our AccuPower® COVID-19 Kits compare to the current standard confirmation assay and the suitability to effective clinical management and control of SARS-CoV-2.

[SY15]
A novel cellular immunotherapy in cancer: CAR-T cell, CAR-NK cell, GMP

A novel cellular immunotherapy (i.e., CAR-T, CAR-NK) has shown promise in treating several types of cancer. In this session, CAR-T cell & CAR-NK cell therapeutics and Good Manufacturing Practices (GMP) & Advanced Regenerative Bio Act will be presented.

[SY16]
MFDS-KSLM
Post-market surveillance and renewal system in MFDS

In the Ministry of Food and Drug Safety (MFDS) and KSLM joint symposium, we will discuss the renewal system of medical devices and development and approval process of IVD of the MFDS. Also, we will notice the proposal of post-market surveillance and plan for collection and evaluation of IVD, and explain the guideline of NGS clinical laboratory accreditation.

[SY17]
Inspector workshop of Korean laboratory accreditation program

This workshop deals with the accreditation checklist and intends to improve understanding and practical skills required of an inspection team leader and team members.